Establishing Minimal Clinically Important Differences in Quality of Life Measures in Opioid-Induced Constipation.

Tack, Jan; Camilleri, Michael; Hale, Martin; Morlion, Bart; Nalamachu, Srinivas; Webster, Lynn; Wild, James

Tack, Jan; Camilleri, Michael; Hale, Martin; Morlion, Bart; Nalamachu, Srinivas; Webster, Lynn; Wild, James.

Affiliation

Tack J; Translational Research Center for Gastrointestinal Disorders, University of Leuven, Leuven, Belgium. Electronic address: jan.tack@kuleuven.be.
Camilleri M; Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, Minnesota.
Hale M; Gold Coast Research, LLC, Plantation, Florida.
Morlion B; Leuven Center for Algology and Pain Management, University Hospital Leuven, University of Leuven, Leuven, Belgium.
Nalamachu S; Mid America PolyClinic, Overland Park, Kansas.
Webster L; PRA Health Sciences, Salt Lake City, Utah.
Wild J; Upstate Clinical Research Associates, Williamsville, New York.

Clin Gastroenterol Hepatol ; 20(4): 855-863, 2022 04.

Article in En | MEDLINE | ID: mdl-33965574

Subject(s)

Chronic Pain; Opioid-Induced Constipation; Analgesics, Opioid/adverse effects; Chronic Pain/drug therapy; Constipation/chemically induced; Constipation/drug therapy; Humans; Minimal Clinically Important Difference; Quality of Life

Key words

Naldemedine; Opioid-Related Disorders; PAMORA

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Chronic Pain / Opioid-Induced Constipation Type of study: Clinical_trials / Prognostic_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Clin Gastroenterol Hepatol Journal subject: GASTROENTEROLOGIA Year: 2022 Document type: Article Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google